 |
Cell-penetrating dominant-negative activating transcription factor 5 |
|---|---|
| Trade Name | |
| Orphan Indication | Glioma |
| USA Market Approval | USA |
| USA Designation Date | 2017-03-20 00:00:00 |
| Sponsor | Sapience Therapeutics, Inc;500 Mamaroneck Avenue, Suite 320;Harrison, New York, 10528 |
Related Access Program